Effect of treatment with natalizumab on ability to work in people with multiple sclerosis: Productivity gain based on direct measurement of work capacity before and after 1 year of treatment

BioDrugs

Volumn 25, Issue 5, 2011, Pages 299-306

  Olofsson, Sara ^a   Wickström, Anne ^b   Häger Glenngård, Anna ^a   Persson, Ulf ^a,c   Svenningsson, Anders ^b  

^a SWEDISH INSTITUTE FOR HEALTH ECONOMICS   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Health economics; Multiple sclerosis; Natalizumab; Productivity costs

Indexed keywords

NATALIZUMAB;

ARTICLE; DISEASE DURATION; DISEASE REGISTRY; DRUG EFFECT; EVALUATION AND FOLLOW UP; FEMALE; HEALTH SURVEY; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PRODUCTIVITY; RECURRENCE RISK; SWEDEN; TREATMENT OUTCOME; WORK CAPACITY;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RETROSPECTIVE STUDIES; SWEDEN; TIME FACTORS; WORK; YOUNG ADULT;

EID: 80053211753     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11593770-000000000-00000     Document Type: Article

References (18)

1. Lucchinetti CF, Brueck W, Rodriguez M, et al. Multiple sclerosis: lessons from neuropathology. Semin Neurol 1998; 18 (3): 337-49 (Pubitemid 28488950)
2. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993 Feb; 116 Pt 1: 117-34 (Pubitemid 23087038)
3. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study, 2: predictive value of the early clinical course. Brain 1989 Dec; 112 Pt 6: 1419-28 (Pubitemid 20024212)
4. Compston A, ColesA.Multiple sclerosis. Lancet 2002Apr 6; 359 (9313): 1221-31 (Pubitemid 34304266)
5. Sundstrom P, Nystrom L, Forsgren L. Incidence (1988-97) and prevalence (1997) of multiple sclerosis in Vasterbotten County in northern Sweden. J Neurol Neurosurg Psychiatry 2003 Jan; 74 (1): 29-32 (Pubitemid 36069032)
6. Ahlgren C, Oden A, Lycke J. High nationwide prevalence of multiple sclerosis in Sweden. Mult Scler 2011 Aug; 17 (8): 901-8
7. Svenningsson A, Runmarker B, Lycke J, et al. Incidence of MS during two fifteen-year periods in the Gothenburg region of Sweden. Acta Neurol Scand 1990 Sep; 82 (3): 161-8 (Pubitemid 20328909)
8. PutzkiN, Fischer J, Gottwald K, et al. Quality of life in 1000 patients with early relapsing-remitting multiple sclerosis. Eur J Neurol 2009 Jun; 16 (6): 713-20
9. Sundstrom P, Nystrom L, Svenningsson A, et al. Sick leave and professional assistance for multiple sclerosis individuals in Vasterbotten County, northern Sweden. Mult Scler 2003 Oct; 9 (5): 515-20 (Pubitemid 37287733)
10. Schulper M. The role and estimation of productivity costs in economic evaluation. In: Drummond M, McGuier A, editors. Economic evaluation in health care. Oxford: Oxford University Press, 2001
11. Berg J, Lindgren P, Fredrikson S, et al. Costs and quality of life of multiple sclerosis in Sweden. Eur J Health Econ 2006 Sep; 7 Suppl. 2: S75-85
12. BiogenIdec. Summary of product characteristics (SPC) for Tysabri (natalizumab) [in Swedish]. FASS.se [online]. Available from URL: http://www. fass.se/LIF/produktfakta/artikel-produkt.jsp?NplID=20040916001115&Doc TypeID=6 [Accessed 2011 Jun 14]
13. O'Connor P. Natalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosis. Expert Opin Biol Ther 2007 Jan; 7 (1): 123-36
14. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebocontrolled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006 Mar 2; 354 (9): 899-910
15. Kobelt G, Berg J, Lindgren P, et al. Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden. Mult Scler 2008 Jun; 14 (5): 679-90 (Pubitemid 351954411)
16. Goodin DS. A questionnaire to assess neurological impairment in multiple sclerosis. Mult Scler 1998 Oct; 4 (5): 444-51 (Pubitemid 28515356)
17. Lechner-Scott J, Kappos L, Hofman M, et al. Can the Expanded Disability Status Scale be assessed by telephone? Mult Scler 2003 Mar; 9 (2): 154-9 (Pubitemid 36426990)
18. Augustsson J, Neovius M, Cullinane-Carli C, et al. Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data froma population-based registry).AnnRheumDis 2010 Jan; 69 (1): 126-31